

# Recognition of Chromosomal DNA inside Cells by Locked Nucleic Acids<sup>†</sup>

Randall Beane,<sup>‡</sup> Sylvie Gabillet,<sup>§</sup> Christophe Montaudou,<sup>§</sup> Khalil Arar,<sup>§</sup> and David R. Corey<sup>\*,‡</sup>

Departments of Pharmacology and Biochemistry, University of Texas Southwestern Medical Center at Dallas, 6001 Forest Park Road, Dallas, Texas 75390-9041, and SIGMA-Aldrich Genopole Campus 1 5, rue Desbruères, 91030 Evry Cedex, France

Received October 14, 2008; Revised Manuscript Received October 30, 2008

**ABSTRACT:** Sequence-selective recognition of DNA inside cells by oligonucleotides would provide valuable insights into cellular processes and new leads for therapeutics. Recent work, however, has shown that noncoding RNA transcripts overlap chromosomal DNA. These RNAs provide alternate targets for oligonucleotides designed to bind promoter DNA, potentially overturning previous assumptions about mechanism. Here, we show that antigene locked nucleic acids (agLNAs) reduce RNA levels of targeted genes, block RNA polymerase and transcription factor association at gene promoters, and bind to chromosomal DNA. These data suggest that the mechanism of LNAs involves recognition of chromosomal DNA and that LNAs are bona fide antigene molecules.

Chromosomal DNA is an important target for molecular recognition by synthetic agents (1). Research over 30 years has examined triple helix-forming agents (2), oligomers that bind through Watson–Crick base pairing (3), and small molecule pyrimidine polyamides (4). These compounds share a common assumption, that recognition would occur through binding to DNA.

Recently, double-stranded antigene RNAs (agRNAs) (we use the term “antigene” to distinguish these short RNAs from similar duplexes that are complementary to mRNA) that target transcription start sites for gene promoters have been shown to modulate gene expression (5–8). The level of expression increases in cell lines where endogenous expression is relatively weak and decreases in a cell line where endogenous expression is relatively strong.

We had initially hypothesized that agRNAs were directly interacting with chromosomal DNA inside cells. However, we discovered that the interaction was mediated by the protein argonaute 2 (AGO2) (6). AGO2 is known to promote formation of RNA–RNA hybrids (9), rather than DNA–RNA hybrids, bringing the likelihood of DNA–RNA binding into question.

We then investigated the molecular target for agRNAs (8). We discovered that DNA was not the only potential target;

there was also a noncoding RNA transcript overlapping the promoter that originated within the target gene and was transcribed in an antisense orientation. We showed that agRNAs were binding to this transcript, recruited AGO protein to the transcript, and that a reduced level of expression of the transcript reversed the action of activating agRNAs. Together, these data suggested that the noncoding RNA, not chromosomal DNA, was the direct target for agRNAs.

The presence of noncoding RNA transcripts that overlap genes is a widespread phenomenon. More than 20% of genes have antisense transcripts, and more than 80% of the genome is transcribed into RNA (10). The purpose of these transcripts is a major unresolved question for biology. What is certain is that these transcripts complicate previously easy assumptions about the mechanism of action of antigene agents originally designed to target chromosomal DNA.

LNA nucleotides contain a methylene bridge connecting the 2'-oxygen of the ribose with the 4'-carbon (11, 12) (Figure 1A). This bridge reduces the conformational flexibility of the ribose and lowers the entropic penalty paid upon hybridization. When placed within DNA or RNA, LNA bases have proven to be effective tools for tailoring the hybridization affinity of oligonucleotides, with a single LNA substitution increasing  $T_m$  values by as much as 5–10 °C (13). LNAs are being tested in clinical trials (14) and appear to be a promising strategy for clinical development.

We recently showed that single-stranded antigene LNAs (agLNAs) that target gene promoters can block gene expression (15). Inhibition is potent, and the protocols for achieving inhibition are simple. Further progress with agLNAs, however, requires an understanding of their mechanism and, fundamentally, whether they are recognizing chromosomal DNA or cellular noncoding RNA.

We introduced agLNAs that are complementary to either progesterone receptor (PR) (16) or androgen receptor (AR) (17) promoters (Table 1 of the Supporting Information) into T47D human breast cancer cells. qPCR (Table 2 of the Supporting Information) revealed a reduction in the levels of PR (Figure 1B, LNA PR2) or AR (Figure 1D, LNA AR1) when cells were treated with complementary agLNAs, relative to addition of a noncomplementary control LNA. Addition of an LNA complementary to the nontemplate strand (LNA PR1) of the PR promoter only marginally

<sup>†</sup> This work was supported by the National Institutes of Health (NIGMS 60642 and NIGMS 73042) and the Robert A. Welch Foundation (I-1244).

\* To whom correspondence should be addressed. Phone: (214) 645-6155. Fax: (214) 645-6166. E-mail: david.corey@utsouthwestern.edu.

<sup>‡</sup> University of Texas Southwestern Medical Center at Dallas.

<sup>§</sup> SIGMA-Aldrich Genopole Campus 1 5.




FIGURE 1: (A) Chemical structures of LNA and ENA bases. (B–D) qPCR data showing the effect of adding LNA and ENA oligomers on mRNA levels of endogenous PR and AR genes. Cells were treated with (A) LNA at 50 nM targeting PR-B or (B) ENA at 50 nM targeting PR-B. (C) Dose–response curve of LNA AR1 showing the relative levels of AR mRNA. Error bars represent the standard deviation among at least three replicates.

reduced PR mRNA levels. Results were confirmed with additional primer sets (Figure 1 of the Supporting Information).

We also transfected cells with a related oligonucleotide chemistry, 2'-O,4'-C-ethylene-bridged nucleic acid (ENA) (Figure 1A). ENA contains an additional methyl group in the 2'–4' carbon bridge and has been shown to increase  $T_m$  values (18). Addition of ENA oligomers (Table 1 of the Supporting Information) to T47D cells also resulted in reduced RNA levels (Figure 1C). Reduction of RNA levels by agLNA and agENA oligonucleotides is consistent with a mechanism that involves binding to chromosomal DNA and a reduction of the level of transcription.

Binding of compounds to transcription start sites would be expected to weaken association of RNA polymerase. To test this hypothesis, we performed chromatin immunoprecipitation (ChIP) on cells treated with either agLNA or a noncomplementary control. RNase was added to all samples to restrict potential targets to DNA. For agLNAs targeting the PR or AR promoters, we observed a reduction in the level of RNA polymerase association upon transfection of oligonucleotide (Figure 2A,D). Reduction of RNA polymerase levels was also observed upon introduction of the ENA-modified oligonucleotide into cells (Figure 2B). Reduction of RNA polymerase occupancy by oligonucleotides containing two different constrained nucleotides (LNA and ENA) in two different genes (PR and AR) is consistent with recognition of chromosomal DNA.

It is also possible that binding to chromosomal DNA will block binding of transcription factors. There is a well-characterized binding site for transcription factor SP1 within




FIGURE 2: Addition of LNA and ENA oligomers reduces the occupancy of RNA polymerase and the SP1 transcription factor at gene promoters. ChIP analysis using qPCR showing the relative occupancy of RNA polymerase II near the PR-B transcription start site following treatment with 50 nM (A) LNA or (B) ENA. (C) Relative occupancies of transcription factor SP1 near the PR-B transcription start site following treatment with 50 nM LNA. (D) RNA polymerase II occupancies near the AR transcription start site following treatment with 50 nM LNA AR24. Error bars represent the standard deviation among three replicates.


the PR promoter (19), so we decided to investigate the effect of agLNAs on SP1 occupancy. Using ChIP, we observed that addition of LNA PR2 reduced levels of SP1 on the PR promoter (Figure 2C), further supporting the hypothesis that recognition occurs through binding to DNA.

Our data on qPCR measurement of RNA levels, ChIP for RNA polymerase, and ChIP for SP1 strongly suggest that agRNAs silence transcription by binding to DNA. To further support the hypothesis that a physical association is occurring between LNA and DNA, we synthesized LNA–biotin conjugates, introduced them into T47D cells, and examined whether biotin–avidin purification would isolate PR promoter chromosomal DNA. Sequences bound to the biotin–LNA conjugate were purified using avidin beads and then amplified by PCR. The amplification used did not employ a reverse transcriptase step and could not amplify RNA.

Cells were transfected with biotin-labeled LNA and cultured for 4 days. Using qPCR, we showed that the biotin-labeled LNA complementary to the template strand of the PR promoter inhibited PR expression in a manner similar to that of analogous unlabeled LNAs (Figure 3A). The biotin-labeled RNA complementary to the nontemplate strand did not significantly reduce PR mRNA levels, similar to what we had observed for the analogous unmodified LNA (Figure 1B).

After demonstrating that the biotin labeling did not effect inhibition of PR expression by the agLNA complementary to the template strand, we used the biotin–avidin purification to test whether the LNA was binding to PR promoter DNA (Figure 3B). The “input” sample was harvested prior to avidin purification and demonstrates that it is possible to amplify the PR promoter in our samples. When no LNA was added, qPCR analysis did not reveal the presence of any PR promoter DNA after purification.

When biotin-labeled LNA PR2 was present, PCR detected DNA corresponding to the PR-B promoter (Figure 3B). These data show that LNA PR2, which targets the template strand of DNA, associates with its chromosomal DNA target. LNA PR1 also associates with chromosomal DNA. LNA PR1 targets the nontemplate strand of DNA and does not reduce protein levels or mRNA levels (Figures 1 and 3) when introduced into T47D cells. Data showing that LNA PR1



**FIGURE 3:** Biotin-labeled LNA inhibits PR gene expression and binds chromosomal DNA at the PR promoter. (A) qPCR data showing the relative levels of mRNA following treatment with 3'-biotin-modified LNAs or a negative LNA control. Error bars show the standard deviation among three replicates. (B) Representative agarose gel showing PCR-amplified DNA (reverse transcriptase was not performed) that associated with a biotin-modified LNA following transfection. "Input" controls were taken prior to addition of the nuclear lysate to avidin-coated beads and ensure that the lysate contains the DNA of interest. Bands labeled "Pull-down" show PCR-amplified DNA following biotin pull-down and elution from avidin-coated beads. Primers corresponding to the PR promoter were used to amplify DNA. Bands were excised from the gel, cloned, and sequenced to verify identity.

binds to chromosomal DNA suggests that the inability of LNA PR1 to inhibit gene expression is not due to a lack of DNA accessibility. We note that inhibition of transcription in cell-free systems by template strand targeted agents, but not similar compounds that target the nontemplate strand, has been observed for oligonucleotides (20) and peptide nucleic acids (21, 22). One concern with experiments in which biotin-avidin purification protocols are applied to living cells is that association may take place after cell lysis. Our lysis buffer (Supporting Information), however, contained divalent cation concentrations that should minimize the likelihood of DNA breathing and discourage strand invasion (23).

Why do agRNAs bind to noncoding transcripts while agLNAs bind to chromosomal DNA? The most likely explanation is that recognition by agRNAs is facilitated by argonaute proteins that have evolved to promote RNA-RNA rather than RNA-DNA recognition. LNAs, by contrast, are well suited to binding duplex DNA without assistance from cellular proteins because of their high-affinity hybridization and resistance to digestion by nucleases.

Taken together, our data support the conclusion that the mechanism for agLNA-mediated inhibition of gene expression involves binding of LNAs to chromosomal DNA. RNA levels are reduced; the levels of association of RNA polymerase and SP1 transcription factor are decreased, and the LNA binds to chromosomal DNA. These results are significant because they suggest that the presence of a noncoding RNA is not necessary for gene inhibition by agLNAs. The ability to directly bind DNA also suggests that agLNAs have potential uses that go beyond inhibition of gene expression. They may be sensitive intracellular probes for transcription factor binding, and our experiments with SP1 provide one example of the potential for this approach.

Chromosome-bound LNAs might also be useful agents for introducing or correcting gene mutations.

## ACKNOWLEDGMENT

We thank Mitsubishi-Kagaku Foods Corp. (MFC), Tokyo, Japan, for generously providing the ENA amidites required for these experiments. ENA is a registered trademark of Mitsubishi-Kagaku Foods.

## SUPPORTING INFORMATION AVAILABLE

Details of LNA and ENA oligomers, cell culture, RNA assays, and ChIP. This material is available free of charge via the Internet at <http://pubs.acs.org>.

## REFERENCES

- Kaihatsu, K., Janowski, B. A., and Corey, D. R. (2004) *Chem. Biol.* 11, 749-758.
- Kalish, J. M., and Glazer, P. M. (2005) *Ann. N.Y. Acad. Sci.* 1058, 151-161.
- Janowski, B. A., Kaihatsu, K., Huffman, K. E., Schwartz, J. C., Ram, R., Hardy, D., Mendelson, C. R., and Corey, D. R. (2005) *Nat. Chem. Biol.* 1, 210-215.
- Nickols, N. G., Jacobs, C. S., Farkas, M. E., and Dervan, P. B. (2007) *ACS Chem. Biol.* 2, 561-571.
- Janowski, B. A., Huffman, K. E., Schwartz, J. C., Ram, R., Hardy, D., Shames, D. S., Minna, J. D., and Corey, D. R. (2005) *Nat. Chem. Biol.* 1, 216-222.
- Janowski, B. A., Huffman, K. E., Schwartz, J. C., Ram, R., Nordsell, R., Shames, D. S., Minna, J. D., and Corey, D. R. (2006) *Nat. Struct. Mol. Biol.* 13, 787-792.
- Janowski, B. A., Younger, S. T., Hardy, D. B., Ram, R., Huffman, K. E., and Corey, D. R. (2007) *Nat. Chem. Biol.* 3, 166-173.
- Schwartz, J. C., Younger, S. T., Nguyen, N., Hardy, D. B., Corey, D. R., and Janowski, B. A. (2008) *Nat. Struct. Mol. Biol.* 15, 842-848.
- Liu, J., Carmell, M. A., Rivas, F. V., Marsden, C. G., Thomson, J. M., Song, J. J., Hammond, S. M., Joshua-Tor, L., and Hannon, G. J. (2004) *Science* 305, 1437-1441.
- Wahlstedt, C. (2006) *Drug Discovery Today* 11, 503-508.
- Koshkin, A. A., Singh, S. K., Nielsen, P., Rajwanshi, V. K., Kumar, R., Meldgaard, M., Olsen, C. E., and Wengel, J. (1998) *Tetrahedron* 54, 3607-3630.
- Obika, S., Nanbu, D., Hari, Y., Andoh, J., Morio, K., Doi, T., and Imanishi, T. (1998) *Tetrahedron Lett.* 39, 5401-5404.
- Vester, B., and Wengel, J. (2004) *Biochemistry* 43, 13233-13241.
- Koch, T., and Orum, H. (2007) *Antisense Drug Technology* (Crooke, S. Ed.) 2nd ed., pp 519-564, Marcel Dekker Inc., New York.
- Beane, R. L., Ram, R., Gabillet, S., Arar, K., Monia, B., and Corey, D. R. (2007) *Biochemistry* 46, 7572-7580.
- Kastner, P., Krust, A., Turcotte, B., Stropp, U., Tora, L., Grone-meyer, H., and Chambon, P. (1990) *EMBO J.* 9, 1603-1614.
- Tilley, W. D., Marcelli, M., and McPhaul, M. J. (1990) *J. Biol. Chem.* 265, 13776-13781.
- Morita, K., Takagi, M., Hasegawa, C., Kaneko, M., Tsutsumi, S., Sone, J., Ishikawa, T., Imanishi, T., and Koizumi, M. (2003) *Bioorg. Med. Chem.* 11, 2211-2226.
- Schultz, J. R., Petz, L. N., and Nardulli, A. M. (2003) *Mol. Cell. Endocrinol.* 201, 165-175.
- Milne, L., Xu, Y., Perrin, D. M., and Sigman, D. S. (2000) *Proc. Natl. Acad. Sci. U.S.A.* 97, 3136-3141.
- Hanvey, J. C., Pepper, N. J., Bisi, J. E., Thomson, S. A., Cadilla, R., Josey, J. A., Ricca, D. J., Hassman, C. F., Bonham, M. A., Au, K. G., et al. (1992) *Science* 258, 1481-1485.
- Nielsen, P. E., Egholm, M., and Buchardt, O. (1994) *Gene* 149, 139-145.
- Zhang, X., Ishihara, T., and Corey, D. R. (2000) *Nucleic Acids Res.* 28, 3332-3338.

BI801930P